Impact of Excess Visceral Abdominal Fat on Cardiovascular Disease
MONTREAL — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (NASDAQ: THTX), a biopharmaceutical company engaged in the development and commercialization of innovative therapies, recently announced significant findings from two poster presentations that highlight the relationship between excess visceral abdominal fat (EVAF) and cardiovascular disease (CVD) risk in people with HIV (PWH).
Findings from IDWeek 2024
At IDWeek 2024, it was revealed that EVAF is a crucial risk factor contributing to increased CVD risk in PWH undergoing modern anti-retroviral therapy (ART). Investigators from the Visceral Adiposity Measurement and Observations Study (VAMOS) presented compelling data that connected EVAF to elevated cardiovascular risks, spotlighting the need for targeted interventions.
Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer of Theratechnologies, emphasized the importance of recognizing EVAF as a significant risk factor. He shared, "These studies reveal that understanding and tackling excess visceral fat can significantly enhance outcomes for those living with HIV who are receiving ART medicines."
Understanding the VAMOS Study
The VAMOS study is the first of its kind aimed at exploring the implications of EVAF in relation to cardiovascular health among PWH on modern ART regimens. This observational study analyzed 170 participants, shedding light on the prevalence of EVAF, which stood at 58%, with an average visceral fat area measured at 148 cm2.
Key Observations from VAMOS Data
Among those with EVAF, significant levels of homeostatic model assessment for insulin resistance (HOMA-IR) and triglyceride-to-high-density lipoprotein (TG:HDL) ratios were noted. The study found a strong correlation between growing visceral fat and increased insulin resistance, indicating that managing EVAF could be vital in reducing cardiovascular risks.
Moreover, the study established that elevated EVAF was linked to a higher risk of atherosclerotic cardiovascular disease (ASCVD) over a decade, demonstrating the profound impact of metabolic health on long-term cardiovascular outcomes.
Exploring Tesamorelin's Effects
Additionally, researchers focused on the role of tesamorelin, a growth hormone-releasing factor (GHRF), in combating EVAF. The analysis from two phase 3 randomized trials revealed promising results in minimizing CVD risks associated with high levels of visceral fat.
Results from Clinical Trials
A trial encompassing 543 PWH examined the change in 10-year ASCVD risk scores before and after 26 weeks of tesamorelin treatment. Although most participants presented with low CVD risks initially, nearly half showed borderline to high risk, underscoring the significance of monitoring cardiovascular health in this demographic.
Through this treatment, participants experienced a modest yet notable reduction in ASCVD risk scores, especially among those who began with higher risks. The findings suggest that tesamorelin's ability to lower total cholesterol presents a potential pathway for improving cardiovascular health in individuals with HIV.
The Importance of IDWeek 2024
Held from October 16 to 19, IDWeek 2024 represented a vital convergence of leading health organizations, amplifying discussions about key topics impacting healthcare, including the interplay of diabetes, liver health, and cardiovascular diseases in the HIV population.
About Theratechnologies
As a dedicated biopharmaceutical entity, Theratechnologies (NASDAQ: THTX) focuses on addressing unmet medical needs through the development of innovative therapies. Further information about their research and products can be found on Theratechnologies' official website and through their public filings.
Frequently Asked Questions
What is the significance of the VAMOS study?
The VAMOS study is pivotal in establishing a link between excess visceral abdominal fat and heightened cardiovascular disease risk in people living with HIV.
How does tesamorelin affect cardiovascular disease risk?
Tesamorelin has shown potential to reduce cardiovascular disease risk by lessening excess visceral abdominal fat in individuals at higher risk.
What was presented at IDWeek 2024 regarding EVAF?
Researchers presented findings indicating that excess visceral abdominal fat is an overlooked risk factor for cardiovascular disease among people living with HIV.
How prevalent is excess visceral abdominal fat in people with HIV?
In the VAMOS study, the prevalence of excess visceral abdominal fat was found to be 58% among the participants.
Why is it important to address EVAF in HIV patients?
Addressing EVAF is crucial as it significantly correlates with increased risks for cardiovascular disease and other metabolic issues, particularly in aging individuals with HIV.
